iSpecimen Inc. (NASDAQ:ISPC) Short Interest Down 81.1% in March

iSpecimen Inc. (NASDAQ:ISPC) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totaling 580,752 shares, a drop of 81.1% from the March 15th total of 3,073,818 shares. Based on an average daily volume of 7,469,230 shares, the days-to-cover ratio is presently 0.1 days. Approximately 6.8% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, iSpecimen presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC bought a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned 0.65% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is owned by hedge funds and other institutional investors.

iSpecimen Price Performance

ISPC stock traded down $0.00 on Friday, reaching $0.13. 359,936,435 shares of the company were exchanged, compared to its average volume of 22,501,070. iSpecimen has a 12 month low of $0.13 and a 12 month high of $3.18. The stock’s fifty day moving average price is $0.24 and its 200 day moving average price is $0.48. The firm has a market capitalization of $1.25 million, a PE ratio of -0.05 and a beta of 1.98.

iSpecimen (NASDAQ:ISPC) last announced its earnings results on Wednesday, April 1st. The company reported ($0.74) earnings per share (EPS) for the quarter. iSpecimen had a negative return on equity of 496.31% and a negative net margin of 543.37%.The company had revenue of $0.05 million for the quarter.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.